2019 Volume 21 Issue 5 Published: 28 October 2019
  

  • Select all
    |
  • Abstract ( ) PDF ( )
    Medication safety is closely related to patient safety. Medication error (ME) is one of the common reasons of patient injury. ME can occur in the links of prescription (medical order) writing and delivery, the storage, dispensing, and distribution of drugs, drug administration and monitoring, medication guidance, drug management, information technology, and etc. Physicians, pharmacists, nurses, and patients are all the possible responsible persons for ME. Everybody should participate in the prevention of ME. In addition to solving the technical problems in management, it is also necessary to advocate a non-punitive medication safety culture and encourage physicians, pharmacists, and nurses to actively participate in the monitoring and reporting of ME. More efforts need to be done on the medication safety in China.
  • Han Shuang, Wu Danwei, Zheng Tingting, Shi Nannan, Zhang Tianjing, Zhang Wei, Zhen Jiancun
    Abstract ( ) PDF ( )
    ObjectiveTo explore the role of chronic disease management led by clinical pharmacists in preventing medication errors in discharged elderly patients with hypertension.MethodsThe subjects were selected from hypertensive patients aged 60-85 years and hospitalized in Department of Cardiology, Beijing Jishuitan Hospital from March 2016 to September 2017. The patients were selected at admission and their basic information were recorded, including gender, age, mode of payment, education level, occupation, and type of combined chronic diseases. The patients were given homogeneous pharmaceutical care by clinical pharmacists during hospitalization and randomly divided into the intervention group and the control group when discharged. After discharge, they were followed up for 24 weeks. The patients in the intervention group were followed up once every 2 weeks from the 1st to the 12th week and once every 4 weeks from the 13th to the 24th week after discharge. The patients in the control group were followed up only once at the end of the 12th and the 24th week after discharge. The follow-up contents included the blood pressure, blood glucose, blood lipids, and other laboratory tests results, name and usage of all the drugs used, on-time medication condition, occurrence of adverse drug reactions, changes in lifestyle, and etc. If the patients were found to have medication errors, the time of error discovery, the content, level, and frequency of the error, and the classification of the drug involved were recorded in a special form. The clinical pharmacists provided individualized medication guidance to patients during the follow-up and gave timely intervention after discovering the medication errors.ResultsForty patients in the intervention group and 44 patients in the control group were entered in the study. There were no significant differences in baseline information between the 2 groups (all P≥0.05). During the 24 weeks of follow-up, medication errors were found in 20 patients in the intervention group and 12 patients in the control group. The difference in detection rate of medication errors between the 2 groups was significant [50.0% (20/40) vs. 27.3% (12/44), χ2=0.043, P=0.032]. A total of 50 cases of medication errors were found in the 2 groups, including 34 (68.0%) in the intervention group and 16 (32.0%) in the control group. During the first 12 weeks of follow-up, 31 cases of medication errors (91.2%) in the intervention group and 8 cases (50.0%) in the control group were found by pharmacists, and the difference was statistically significant (P=0.002). The difference in the proportion of different medication errors classification between the 2 groups was not significant (P>0.05). The drug omission was with the highest proportion in the 2 groups [47.1% (16/34) in the intervention group and 31.2% (5/16) in the control group].Among 50 cases of medication errors, 49 (98.0%) were defined as level 2 errors (with mistake, but no harm), including 20 cases of grade C errors and 29 cases of grade D errors; 1 (2.0%) was defined as level 3 (with mistake and harm) and grade F error. After the intervention of clinical pharmacists, all the level 2 errors were corrected. Level 3 errors led to re-hospitalization of patients. After pharmacists and physicians emphasized the importance of taking medicine according to doctor′s orders again, patients did not make medication errors again. There are 8 categories and 22 kinds of drugs involved in medication errors, including antiplatelet, antihypertensive, hypolipidemic, hypoglycemics, anti-gout, antiarrhythmic, anticoagulant, and anti-angina drugs.ConclusionChronic disease management led by clinical pharmacists is helpful to find and correct the medication errors timely in discharged elderly patients with hypertension.
  • Shan Wenya, Jiang Saiping, Liu Fang, Lu Xiaoyang
    Abstract ( ) PDF ( )
    ObjectiveTo analyze the risks of high alert drug concentrated potassium chloride injection in clinical application using failure mode and effect analysis (FMEA) method and make the relevant prevention measures.MethodsA study team was established in the First Affiliated Hospital, Zhejiang University. The risk points in the application process of concentrated potassium chloride injection through literature search, questionnaires, and on-the-spot investigations were collected. Severity(S), frequency of occurrence(O), and likelihood of detection(D) of the risks related to these failure modes were scored and the risk priority numbers (RPN) were determined. The failure modes with RPN >10.0 or their severity up to 5.0 were screened out and the corresponding prevention strategies were formulated.ResultsFive risk points were collected through literature search; 10 risk points were obtained through questionnaires, including 3 from physicians, 3 from pharmacists, and 4 from nurses; and 5 risk points were obtained through on-the-spot investigations. Sixteen risk points with RPN > 10.0 or severity up to 5.0 were further screened from the above links, including 3 from information system links, 2 from drug storage links, 4 from doctor prescription links, 4 from pharmacist dispensing links, and 3 from nurse administration links. According to the selected risk points, 22 prevention strategies were formulated. The prevention measures for the above 5 links were 4, 4, 6, 5, and 3, respectively, including 11 mandatory strategies, 9 recommended strategies, and 2 conditional strategies.ConclusionThe risk points of concentrated potassium chloride injection application can be screened using FMEA method, which is helpful to formulate the preventive strategies for medication errors related to the drug.
  • Li Yunsong, Lin Min, Chen Quanyao, Wang Lingsong, Chen Yao
    Abstract ( ) PDF ( )
    ObjectiveTo understand the occurrence and main characteristics of medication errors (ME) in Xiamen Maternal and Child Health Hospital.MethodsAll the ME reports received by the ME submission system of Xiamen Maternal and Child Health Hospital from January 1, 2015 to December 31, 2017 were collected, and ME characteristics such as the time of occurrence, classification, grade, drugs involved, and triggering factors were analyzed. On the basis of the 9-level grading method (grade A-I), ME were further divided into potential errors (including potential error problems and errors that happened but the drugs were not given to patients) and out-door errors (the wrong drugs had been given to patients).ResultsA total of 18 944 ME reports were collected, including 12 ME that occurred before the link of prescription and did not involve patients and 18 932 ME that occurred in the link of prescription and various links after the prescription. Of the 18 932 ME, 231 were out-door errors, which accounted for 1.22% of overall ME. A total of 3 553 074 patients (number of registrations)were prescribed in the study period in the hospital and the incidences of overall ME and out-door errors were 0.53% (18 932/3 553 074) and 0.07‰ (231/3 553 074), respectively. The highest incidences of both the potential errors and out-door errors appeared from 13: 00 to 13: 59 [21.87‰(1 120/51 248);0.18‰(9/51 248)]. The top 3 ME classes in the 18 944 ME were prescription errors (77.37%, 14 657 ME), dispensing and location errors (17.35%, 3 286 ME), and omission and delivering errors (2.22%, 421 ME). Of the 18 944 ME,6 (0.03%), 18 821 (99.35%), 111 (0.59%), and 6 (0.03%) ME were grading as A, B, C, and D, respectively, while none was grading as E-I. Personnel factor took the first place [59.65% (11 301/18 944)] in all the triggering factors of ME, followed by environmental factor [17.71% (3 355/18 944)].ConclusionsThe incidence of overall ME in Xiamen Maternal and Child Health Hospital was 0.53% and most of the ME were not serious, which were no harm to patients. The peak time of the ME occurrence lasted from 13: 00 to 13: 59. Prescription error was the main type of ME and the main trigger factor was personnel factor . Results of the study could help to develop targeted precautions to reduce the occurrence of ME.
  • Wang Jing, Chen Can, Wang Xiaocheng, Zhou Min, He Juanhua, Liao Hui, Li Yuanping
    Abstract ( ) PDF ( )
    ObjectiveTo evaluate the relationship between proton pump inhibitor (PPI) and the risk of spontaneous bacterial peritonitis (SBP) in cirrhosis patients systematically.MethodsThe literature on the related databases as of February 2019 was searched. Case-control studies, cohort studies, and randomized controlled studies (RCT), which set the theme as the relationship between PPI and SBP in cirrhosis patients, whose main outcome indicator was SBP incidence, and which had high quality assessed by Newcastle-Ottawa Scale or modified Jadad scoring method, were collected. The meta-analysis was performed using Rev Man 5.3 software.ResultsA total of 18 studies were enrolled in the meta-analysis. Of the 18 studies, 8 were case-control studies, 9 were cohort studies, and 1 was RCT; 6 were prospective studies and 12 were retrospective studies; 13 were single-center studies and 5 were multi-center studies. A total of 6 961 patients were included, 3 353 in the trial group and 3 608 in the control group. The patients in the trial group received PPI alone and the patients in the control group did not receive any acid-suppressing drug. Overall analysis of the 18 studies showed that the risk of SBP in patients in the trial group was markedly higher than that in the control group (OR=1.83, 95%CI: 1.43-2.33, P<0.001). The results of subgroup analysis for 8 case-control studies showed that the risk of SBP in patients in the trial group was markedly higher than that in the control group(OR=2.38, 95%CI: 1.69-3.36, P<0.001). The results of subgroup analysis for 9 cohort studies showed that the risk of SBP of patients in the trial group was markedly higher than that in the control group (OR=1.27, 95%CI: 1.04-1.55, P=0.020). The results of subgroup analysis for 12 retrospective studies showed that the risk of SBP in patients in the trial group was markedly higher than that in the control group (OR=1.81, 95%CI: 1.34-2.45, P=0.001). The results of subgroup analysis for 6 perspective studies showed that the risk of SBP in patients in the trial group was markedly higher than that in the control group (OR=1.88, 95%CI: 1.27-2.79, P=0.002). The results of subgroup analysis for 13 single-center studies showed that the risk of SBP in patients in the trial group was markedly higher than that in the control group (OR=1.97, 95%CI: 1.41-2.76, P<0.001). The results of subgroup analysis for 5 multicenter studies showed that the risk of SBP in patients in the trial group was markedly higher than that in the control group (OR=1.69, 95%CI: 1.33-2.13, P<0.001). ConclusionsPPI can increase the risk of SBP in patients with liver cirrhosis. It is suggested that PPI be used cautiously in patients with liver cirrhosis.
  • Lin Zhiqiang, Wu Ruihong, Xiao Jianxiong, Zhou Yong, Zhang Shanying, Zheng Kuicheng
    Abstract ( ) PDF ( )
    ObjectiveTo evaluate the safety of national immunization program (NIP) vaccines and non-NIP vaccines in Fujian Province from 2011 to 2015.MethodsThe adverse events following immunization (AEFI) case information reported in Fujian Province from 2011 to 2015 was collected from the National AEFI Information Management System and vaccination data of NIP vaccines (11 species) and non-NIP vaccines (19 species) in the same period in Fujian Province were collected from the National Immunization Program Information Management System. The collected monitoring data were descriptively analyzed. The total and severe AEFI reporting rates and their 95% confidence intervals (CI) were calculated.ResultsFrom 2011 to 2015, a total of 70 976 300 doses of vaccines were inoculated in Fujian Province and a total of 8 987 cases of AEFI were reported, including 192 cases (2.14%) of severe AEFI. The incidence (95%CI) of reported AEFI was 12.66 (12.40-12.93) per 100 000 doses and the incidence (95%CI) of reported severe AEFI was 2.71 (2.34-3.12) per one million doses. A total of 55 702 100 doses of NIP vaccines were inoculated and 7 347 cases of AEFI were reported, of which 138 (1.88%) were severe AEFI cases. The incidence (95%CI) of reported AEFI was 13.19 (12.89-1.49) per 100 000 doses of NIP vaccines and the incidence (95%CI) of reported severe AEFI was 2.48 (2.08-2.93) per one million doses. Among the 11 NIP vaccines, the incidence (95%CI) of reported AEFI ranged from 0.95 (0.88-1.13) per 100 000 doses to 43.71 (40.72-46.75) per 100 000 doses and the incidence (95%CI) of reported severe AEFI ranged from 1.04 (0.32-1.76) per one million doses to 6.41 (2.78-10.04) per one million doses. A total of 15 271 600 doses of non-NIP vaccines were inoculated and 1 640 cases of AEFI were reported, of which 54 (3.54%) were severe AEFI cases. The total incidence (95%CI) of reported AEFI was 10.74 (10.23-11.27) per 100 000 doses and the incidence (95%CI) of reported severe AEFI was 3.54 (2.66-4.61) per one million doses. Among the 19 non-NIP vaccines, the incidence (95%CI) of reported AEFI ranged from 2.06 (0.38-3.71) per 100 000 doses to 45.22 (35.29-55.10) per 100 000 doses and the incidence (95%CI) of reported severe AEFI ranged from 0.52 (0-1.53) per one million doses to 20.89 (0-44.51) per one million doses.ConclusionFrom 2011 to 2015, the incidences of reported AEFI and severe AEFI for NIP and non-NIP vaccines circulated in Fujian Province were low, which had good safety.
  • Zhang Zhicui, Wu Shihua, Zhen Ji
    Abstract ( ) PDF ( )
    ObjectiveTo explore the efficacy and safety of dezocine after laparoscopic cholecys-tectomy at a high altitude area (average altitude of over 4 500 m).MethodsThe study was designed as an open randomized controlled study. The subjects were selected from patients who underwent laparoscopic cholecystectomy and required postoperative analgesia in Duilongdeqing District People′s Hospital of Lhasa. The patients were randomly divided into the observation group and the control group. They had the same anesthesia method during operation and patient-controlled intravenous analgesia (PCIA) was initiated after the operation. The patients in the observation group were treated with dezocine 0.6 mg/kg plus ondansetron 16 mg diluted in 0.9% sodium chloride injection 100 ml for PCIA, while in the control group, dezocine was replaced by sufentanil 2 μg/kg. According to the difference in the incidence of excessive sedation between dezocine and sufentanil in previous literature, it was estimated that the sample size in the 2 groups should be >14 cases and the patients should be terminated when the test efficacy was >0.8. Visual analogue scale (VAS) score (pain evaluation) and Ramsay sedation scale (sedation evaluation) at 1, 4, 8, 12, 24 and 48 hours, frequency of PCIA pump pressing and dosage of anesthetics, and the incidence of adverse events related to analgesics within 48 hours after operation in patients in the 2 groups were compared.ResultsFrom January 2015 to November 2017, a total of 50 patients were enrolled in the study, including 25 in the observation group and 25 in the control group. The differences in gender, age, weight, American Society of Anesthesiologists classification, operation time, frequency of PCIA pump pressing and dosage of anesthetics between the 2 groups  were not significant (P>0.05 for all). The differences in VAS scores at all time points after operation were not significant (P>0.05 for all). The Ramsay sedation scores in patients in the observation group at 1 and 4 hours after operation were significantly lower than those in the control group [(2.5±1.1) score vs. (3.4±1.4) score, P=0.016; (2.5±1.0) score vs. (3.5±1.5) score, P=0.007]. The incidences of sedation-related adverse events such as nausea, vomiting, respiratory depression within 48 hours after operation in the control group were significantly lower than those in the control group[8.0% (2/25) vs. 36.0% (9/25), 0 vs. 24.0% (6/25), 4.0% (1/25) vs. 44.0% (11/25), P<0.05 for all].ConclusionsThe analgesic effect of dezocine after laparoscopic cholecystectomy at high altitudes was similar to that of sufentanil and the incidences of respiratory depression and excessive sedation were lower than those of sufentanil. Dezocine may be safer for patients at high altitudes.
  • He Yayi, Shi Bingyin
    Abstract ( ) PDF ( )
    ObjectiveTo explore the clinical characteristics of Graves′disease patients with methimazole-induced agranulocytosis combined with septicemia.MethodsThe study was based on a previous retrospective analysis of the clinical data in Graves′ disease patients admitted to the First Affiliated Hospital of Xi′an Jiaotong University from January 2000 to December 2015 due to antithyroid drug-induced agranulocytosis and focused on the 7 patients who developed agranulocytosis combined with septicemia (septicemia group) after taking methimazole. Relevant data was re-extracted from the medical records of the 7 patients. The clinical characteristics of patients with septicemia were explored through the analysis on their clinical manifestations, bacteriological characteristics, treatment and outcomes, and the comparison of above contents with those of the 55 patients with methimazole-induced agranulocytosis without septicemia (non-septicemia group). ResultsSeven patients in the septicemia group were female, aged 20 to 56 years. Of the 7 patients, 3 combined with hyperthyroid heart disease, 1  combined with life-threatening thyrotoxicosis; 6 patients with multiple organ infections (2 with suppurative tonsillitis and pulmonary infection; 2 with suppurative tonsillitis and gastrointestinal infection; 1 with suppurative tonsillitis, pulmonary infection, and submandibular abscess; 1 with suppurative tonsillitis, pulmonary infection, and periodontal abscess) and 1 patient with pulmonary infection alone. The main clinical symptoms of patients with septicemia included fever, sore throat, anorexia, and palpitations. The proportions of patients with suppurative tonsillitis, lung infections, and the lowest absolute neutrophil count (ANC) value of 0 in the septicemia group were higher than those in the non-septicemia group [6/7 vs. 43.6% (24/55), 5/7 vs. 21.8% (12/55), and 5/7 vs. 29.1% (16/55)]. The minimum white blood cell count in patients in the septicemia group was significantly lower than those in the non-septicemia group[0.23 (0.17, 0.60)×109/L vs. 0.92 (0.50, 1.47)×109/L]. The duration of fever, recovery time of agranulocytosis, and hospitalization days in patients in the septicemia group were significantly longer than those in the non-septicemia group [13 (7, 21) d vs. 6(3, 9) d and 29 (17, 37) d vs. 14 (9, 21) d]. The differences were all statistically significant (P<0.05 or P<0.01). After the diagnosis of agranulocytosis, methimazole was stopped in all patients. Their septicemia was effectively controlled and ANC returned to normal after the treatments with broad-spectrum antibiotics, recombinant human colony-stimulating factor (rhG-CSF), and glucocorticoids.ConclusionsGraves′disease patients, who developed agranulocytosis combined with septicemia after taking methimazole, often had multiple organ infections. Their clinical symptoms were critical and difficult to treat. The early and rational application of broad-spectrum antibacterial drugs and simultaneous treatments with rhG-CSF and glucocorticoids were expected to improve patients′outcomes.
  • Li Yuan
    Abstract ( ) PDF ( )
    Sodium-glucose co-transporter 2 (SGLT2) inhibitors are new antihyperglycemics, which reduce blood glucose by selectively inhibiting the activity of SGLT2 and reducing the reabsorption of glucose in proximal convoluted tubules. One of the major safety problems of SGLT-2 inhibitors is the possibility of urogenital system infections due to increased local glucose levels in the urogenital tract. The incidences of urinary tract infections in patients with dapagliflozin, canagliflozin, empagliflozin, and ertugliflozin treatments were 4.4%-11.4%, 4.9%-8.3%, 5.0%-15.6%, and 3.2%-7.2%, respectively; and the incidences of genital infections were 6.2%-13.0%, 6.2%-13.4%, 2.3%-9.5%, and 2.1%-10.0%, respectively. The main manifestations of urinary tract infection are urethritis and cystitis and conventional anti-infection therapy are effective. Candida is the most common pathogen in reproductive system infections. The clinical features of reproductive system infections in most females are vulvovaginitis, in fewer females are pelvic inflammation and genital warts, which occur mostly within the first 4 months of medication; while the clinical features in most males are balanitis and balanoposthitis, in fewer males are epididymo-orchitis and genital warts, which mostly occur in the first year of medication. Urogenital system infections in most patients cure quickly after treatments, rarely leading to withdrawal of SGLT2 inhibitors. However, severe reproductive system infections (such as Fournier′s gangrene) caused by SGLT2 inhibitors have also been reported. During the treatment with SGLT2 inhibitors, it is necessary to strengthen patient monitoring and the education on related knowledge so as to minimize the inducing factors of urogenital system infections. Once an infection occurs, it should be treated timely.
  • Shao Rong, Tao Tiantian
    Abstract ( ) PDF ( )
    In order to establish a more powerful legal guarantee for drug administration, the Drug Administration Law of the People′s Republic of China (PRC) was revised systematically for the second time in August 2019. In this revision, taking public health as its foothold, a scientific and strict legal system was established to guarantee the medication safety and legitimate right of the public by ensuring the quality of drugs, which is of great significance to promote the scientific, modern, and legal process of drug safety management in China. In this paper, taking medication safety of patient as starting point, through analysis on the general principles and core clauses of the law, the legal framework, sympathetic drug use, marketing authorization holder system, legal liability for illegal acts, Good Manufacture Practice of Medical Products (GMP) dynamic inspection system, and new definition of counterfeit drugs in the context of the new drug administration law were interpreted.
  • Zhang Shiliang
    Abstract ( ) PDF ( )
    A 44-year-old female patient took by herself compound Ganmaoling granules 10 g thrice daily orally for a cold. Two days later, the patient developed yellowish sclera and urine, and then the drug was stopped. The next day, her urine color became darker, her skin turned yellow, and she developed fatigue, nausea, vomiting, and etc. On day 4 of onset, laboratory tests showed alanine aminotransferase (ALT) 1 276 U/L, aspartate aminotransferase (AST) 1 042 U/L, total bilirubin (TBil) 208.2 μmol/L, direct bilirubin (DBil) 165.0 μmol/L, and negative hepatitis B related serological markers. On day 6 of onset, the possibility of patients suffering from hepatitis A, C, D and E was excluded by laboratory tests results. Her liver injury was considered to be related to the compound Ganmaoling granules. IV infusions of compound glycyrrhizin injection, ademetionine 1,4-butanedisulfonate for injection, and reduced glutathione for injection and dicyclol tablets orally were given. After treatments, her symptoms gradually improved, and basically disappeared on  day 23 after hospitalization. A reexamination of liver function showed ALT 15 U/L, AST 29 U/L, TBil 59.6 μmol/L, and DBil 47.9 μmol/L.
  • Zhang Yan, Hu Linkun, Gao Jie
    Abstract ( ) PDF ( )
    A 56-year-old female patient received triple-drug immunosuppressive therapy after allogenic renal transplantation, including tacrolimus 3 mg twice daily, mycophenolate mofetil 500 mg twice daily, and prednisone 20 mg once daily. The patient received compound sulfamethoxazole 0.48 g once daily for prevention of infection a month after operation. The laboratory tests showed that the levels of tacrolimus blood concentration (CTac), serum creatinine (Scr), and blood potassium were 6.56 μg/L, 142 μmol/L, and 4.3 mmol/L, respectively before medication, 12.13 μg/L, 147 μmol/L, and 7.1 mmol/L after 1 week of compound sulfamethoxazole treatment, and 16.72 μg/L, 176 μmol/L, and 8.3 mmol/L after 2 weeks, accompanied by lassitude and weakness of the feet. Compound sulfamethoxazole was stopped, potassium-lowering therapy was given, the dose of tacrolimus was reduced to 2 mg twice daily, and mycophenolate mofetil and prednisone were given at the same doses as before. Laboratory tests showed Scr 175 μmol/L and blood potassium 4.7 mmol/L on day 3 of compound sulfamethoxazole withdrawal and CTac 7.13 μg/L, Scr 150 μmol/L, and blood potassium 4.8 mmol/L on day 8. The patient took compound sulfamethoxazole 0.48 g twice daily again according to the doctor′s advice, and 2 weeks later, her blood potassium increased to 6.2 mmol/L. The dose of compound sulfamethoxazole was gradually reduced firstly to 0.48 g once daily, then to 0.48 g every other day, and was completely stopped 8 weeks later. Two weeks after drug withdrawal, her blood potassium decreased to 4.6 mmol/L. Hyperkalemia did not recur.
  • Sun Zhihui, Zhang Hongmei, Hou Jiqiu, Li Yanhua
    Abstract ( ) PDF ( )
    A 59-year-old female patient received liver-protective drugs such as compound glycyrrhizin for liver cirrhosis and anti-infective agent piperacillin sodium and sulbactam sodium (2.5 g by an IV infusion, twice daily) for pneumonia, with the precondition of negative skin test. On day 4, the patient developed scattered small maculopapular rashes on her face, which then increased all over the body, located mainly in the trunk, and appeared as red round and irregular shapes, accompanied by local swelling of the mouth, and chapped lips. Considering that it was caused by piperacillin sodium and sulbactam sodium, the drug was discontinued and symptomatic and supportive treatments with methylprednisolone, desloratadine cirate disodium, and appropriate topical drugs were given immediately. Liver-protective drugs were continued and moxifloxacin was given for infection. On day 2 of drug withdrawal, the patient developed nasal and scattered skin desquamation on the nose and neck. Exfoliative dermatitis was diagnosed. On day 8 of admission, the erythema on the whole body became lighter, no new skin rashes appeared, and methylprednisolone was stopped. On day 13, the patient′s original rashes became lighter, crusted, and partially subsided.
  • Li Jinfeng, Qu Guanghong, Zhang Yuan
    Abstract ( ) PDF ( )
    A 31-year-old male patient received carbamazepine and mecobalamin for 2 weeks due to trigeminal neuralgia. After 15 days of drug withdrawal, the patient developed fever, sore throat, fatigue, and diffuse bright red maculopapular rashes in the trunk, accompanied by itching, which progressively worsen. Laboratory tests showed white blood cell count 13.1×109/L, neutrophil count 10.7×109/L, eosinophil count 0.5×109/L, C-reactive protein 807.5 mg/L, alanine aminotransferase 663 U/L, and aspartate aminotransferase 332 U/L. Drug-induced hypersensitivity syndrome was diagnosed in the clinical. Anti-allergic and liver-protective drugs such as methylprednisolone, human immunoglobulin, compound glycyrrhizin, reduced glutathione, and etc. were given. Nineteen days later, the symptoms improved and the patient was discharged. At 2 weeks of follow-up, the patient showed normal blood routine test and liver function test results. According to the drug labels and the literature, it was considered that the drug-induced hypersensitivity syndrome was likely to be caused by carbamazepine.
  • ang Xuemin, Shen Baorong, Liu Pengyuan, Yang Kaining, Zhao Qian, Wang Mengmeng
    Abstract ( ) PDF ( )
    A 30-year-old female patient received oral rifampicin 0.562 5 g (before breakfast) and isoniazid 0.4 g (after dinner) for pulmonary tuberculosis. There were no abnormalities in her blood routine and liver function indexes before medication. Three days after the medication, the patient developed fatigue, nausea, and vomiting. The next-day laboratory tests showed white blood cell count 1.1×109/L, neutrophil count 0.32×109/L, hemoglobin (Hb) 120 g/L, platelet count (PLT) 149×109/L, alanine aminotransferase (ALT) 368 U/L, aspartate aminotransferase (AST) 1 333 U/L, total bilirubin (TBil) 19.7 μmol/L, and direct bilirubin (DBil) 6.6 μmol/L. Liver injury and neutropenia were diagnosed. Considering the reason from current medication, rifampicin and isoniazid were discontinued and liver-protective and symptomatic treatments were given. On day 4 of the withdrawal, the patient′s symptoms improved and laboratory tests showed neutrophil count 1.50×109/L, ALT 163 U/L, AST 139 U/L, TBil 9.0 μmol/L, and DBil 3.7 μmol/L. On day 7 of the withdrawal, the patient′s liver function improved (ALT 75 U/L, AST 33 U/L, TBil 6.4 μmol/L, and DBil 3.3 μmol/L) and her neutrophil count was 1.60×109/L. One week after discharge, the neutrophil count was 1.70×109/L; the levels of ALT, AST, TBil, and DBil were 30 U/L, 34 U/L, 10.0 μmol/L, and 4.2 μmol/L, respectively .
  • He Zhongfang, Yang Qingqing, Lu Yaqin, Jiang Zhenxiu, Liu Zhaodong, Liang Li
    Abstract ( ) PDF ( )
    A 63-year-old female patient received IV infusions of salvianolate, cattle encephalon glycoside, and pantoprazole and an intramuscular injection of diphenhydramine (only once) in Emergency Department for dizziness, nausea, vomiting, and weakness of lower limbs. Laboratory tests showed no abnormalities in liver function. Craniocerebral CT showed multiple lacunar ischemic demyelination and bilateral internal carotid atherosclerosis. The patient was diagnosed with lacunar cerebral infarction and admitted to hospital. On the night of admission, oral rosuvastatin calcium 10 mg/d and clopidogrel 75 mg/d were given. Eleven hours later, laboratory tests showed aspartate aminotransferase (AST) 254 U/L and alanine aminotransferase (ALT) 157 U/L. Salvianolate and pantoprazole were discontinued and reduced glutathione was given. On day 3 of reduced glutathione treatment, laboratory tests showed AST 587 U/L and ALT 660 U/L. Rosuvastatin calcium-induced liver transaminase elevation was considered. Then rosuvastatin calcium was discontinued and compound glycyrrhizin was given. On day 9 of rosuvastatin calcium withdrawal, laboratory tests showed AST 112 U/L and ALT 201 U/L, and then reduced glutathione was discontinued. On day 15 of rosuvastatin calcium withdrawal, laboratory tests showed AST 42 U/L and ALT 63 U/L, and then compound glycyrrhizin was discontinued. The patient was discharged 4 days later. At 2 weeks of follow-up, no abnormalities in liver function were found in the patient.
  • Wang Rui, Zhang Wenrui, Wang Xiangfeng, Zhang Yongkai
    Abstract ( ) PDF ( )
    An 8-month-old female infant received propranolol 2 mg orally twice daily and prednisone 7.5 mg orally once daily for kaposiform hemangioendothelioma. Due to poor efficacy, propranolol and prednisone were discontinued and sirolimus 0.2 mg was given orally twice daily. The child′s liver function was normal before sirolimus treatment. On day 10 of sirolimus treatment, the laboratory tests showed alanine aminotransferase(ALT) 58 U/L, aspartate aminotransferase(AST) 116 U/L, γ- glutamyltransfarase(γ-GT) 84 U/L, alkaline phosphatase(ALP) 181 U/L, total bile acid(TBA) 109.2 μmol/L, total bilirubin(TBil) 57.4 μmol/L, and direct bilirubin(DBil) 38.0 μmol/L. At the same time, the child developed decrease of appetite, milk refusal, and cry and scream all the time. The physical examination showed slightly yellow on her skin and sclera. Cholestatic liver injury caused by sirolimus was considered. Sirolimus was discontinued and liver-protective therapy and drugs for anti-jaundice were given. On day 6 of drug withdrawal, the laboratory tests showed ALT 58 U/L, AST 116 U/L, γ-GT 84 U/L, ALP 181 U/L, TBA 109.2 μmol/L, TBil 41.5 μmol/L, and DBil 20.8 μmol/L; the child′s appetite recovered, yellowish skin and sclera improved markedly. On day 20 of drug withdrawal, the child was discharged. No abnormalities were found in the child′s liver function after 15 days of discharge.
  • Yu Zhipeng, Qian Yulan
    Abstract ( ) PDF ( )
    A 76-year-old female patient received one perindopril and indapamide tablet (containing perindopril 4.00 mg and indapamide 1.25 mg in each tablet) once daily for hypertension. Her blood pressure was well controlled. One month later, the patient was admitted to hospital for hyperglycemia. On day 2 of admission, the patient developed fever, with the highest body temperature of 38.4 ℃. Laboratory tests showed that her white blood cell count(WBC) was 1.7×109/L and neutrophils count was 0.38×109/L, which was considered to be related to perindopril and indapamide. Then perindopril and indapamide was discontinued and replaced by amlodipine besylate. And recombinant human granulocyte colony stimulating factor, leucogen, vitamin B4, and anti-infective drugs were also given. On the second day of treatment, the WBC was 6.0×109/L and neutrophils count was 4.05×109/L. The patient′s body temperature returned to normal on day 6 of admission and her WBC, neutrophils count, blood glucose, and blood pressure were 6.2×109/L, 4.55×109/L, 6.7 mmol/L, and 128/79 mmHg, respectively on day 8.
  • Zhang Hongmei, Hou Jiqiu, Sun Lirui, Zhou Wei
    Abstract ( ) PDF ( )
    A 30-year-old male patient received pancreatin enteric-coated capsules 0.45 g thrice daily with meals for chronic pancreatitis. On day 9 of medication, the patient developed discomfort in the right first metatarsophalangeal joint. The next day, his symptoms were aggravated, manifested by metatarsophalangeal joint pain and swelling. Laboratory tests showed an increase of uric acid (477 μmol/L), which was considered to be gouty arthritis induced by pancreatin enteric-coated capsules. Then the drug was discontinued and symptomatic treatments such as alkaline urine and analgesics were given. On day 5 of drug withdrawal, the swelling of the right metatarsophalangeal joint was markedly alleviated and the tenderness was significantly relieved. On day 8 of drug withdrawal, swelling and pain in the patient′s right metatarsophalangeal joint disappeared and his uric acid level was 430 μmol/L. The patient was discharged. At 2 weeks of follow-up, his uric acid returned to normal.
  • Zeng Na, Sun Huajun
    Abstract ( ) PDF ( )
    A 4-year-old boy with influenza A virus infection and pharyngitis received oral oseltamivir phosphate capsules 30 mg twice daily, compound pholcodine oral solution 4 ml thrice daily, and paracetamol oral suspension 4 ml as required according to the doctor′s advice. About 10 and 13 hours after the first administration of oseltamivir phosphate capsules, the boy suddenly woke up from sleep at night, closed his eyes, clenched his hands, and shouted. The above symptoms lasted about 20 minutes. About 6, 14 and 18 hours after the second administration of the drug, the above symptoms of mania appeared again. It was considered that the mania was related to oseltamivir phosphate capsules. Oseltamivir phosphate capsules were stopped and the other drugs were continued. The symptoms of mania did not recur in the boy since then.